

May 12, 2026

News Release

Company: Olympus Corporation

Bob White, Director, Representative Executive Officer, President and CEO

(Code: 7733, Prime, Tokyo Stock Exchange)

Contact: Takaaki Sakurai, Vice President, Investor Relations

TEL: +81-42-642-2111

### Notice Concerning the Difference Between Financial Guidance and Actual Results for the Fiscal Year 2026

Olympus Corporation ("Olympus") hereby announces that a difference has arisen between the consolidated financial guidance for the fiscal year ended March 31, 2026 (April 1, 2025 to March 31, 2026, "FY2026"), which was announced on February 13, 2026, and the actual results announced today, as described below.

#### 1. Difference Between Consolidated Financial Guidance and Actual Results for FY2026

	Revenue	Operating profit	Adjusted operating profit	Profit before tax	Profit attributable to owners of parent	Basic earnings per share
	(¥ million)	(¥ million)	(¥ million)	(¥ million)	(¥ million)	(¥)
Previous guidance (A)	998,000	87,000 to 75,000	139,000 to 127,000	83,000 to 71,000	59,000 to 50,000	53.07 to 44.97
Actual results (B)	1,010,676	97,120	143,310	93,994	68,172	61.32
Change (B-A)	+12,676	+10,120 to +22,120	+4,310 to +16,310	+10,994 to +22,994	+9,172 to +18,172	—
Change %	+1.3	+11.6 to +29.5	+3.1 to +12.8	+13.2 to +32.4	+15.5 to +36.3	—
(Reference) Results for the previous fiscal year (Fiscal year ended March 2025)	997,332	162,462	188,509	159,070	117,855	102.99

(Note) The Orthopedic Business has been classified as a discontinued operation from the first quarter of FY2025. Due to this, the amounts presented for revenue, operating profit and profit before tax are the amounts from continuing operations. The amounts presented for profit attributable to owners of parent are aggregates of continuing operations and discontinued operation.

## 2. Reasons for the Difference

Primarily in the Gastrointestinal Solutions business, sales exceeded the previously announced guidance due to successful promotional activities in the North American market for endoscopes equipped with EDOF (Extended Depth of Field) technology and the “EU-ME3” endoscopic ultrasound system. In addition, gains from the sale of overseas real estate were recorded as other income, resulting in all profit metrics exceeding the previously announced guidance.